These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28238745)

  • 1. Seasonal variability of severe asthma exacerbations and clinical benefit from lebrikizumab.
    Staton TL; Arron JR; Olsson J; Holweg CTJ; Matthews JG; Choy DF
    J Allergy Clin Immunol; 2017 May; 139(5):1682-1684.e3. PubMed ID: 28238745
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.
    Hanania NA; Korenblat P; Chapman KR; Bateman ED; Kopecky P; Paggiaro P; Yokoyama A; Olsson J; Gray S; Holweg CT; Eisner M; Asare C; Fischer SK; Peng K; Putnam WS; Matthews JG
    Lancet Respir Med; 2016 Oct; 4(10):781-796. PubMed ID: 27616196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-interleukin 5 Therapy for Eosinophilic Asthma: a Meta-analysis of Randomized Clinical Trials.
    Wang FP; Xiong XF; Liu T; Li SY; Cheng DY; Mao H
    Clin Rev Allergy Immunol; 2018 Apr; 54(2):318-330. PubMed ID: 27677499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the September asthma epidemic.
    Sears MR; Johnston NW
    J Allergy Clin Immunol; 2007 Sep; 120(3):526-9. PubMed ID: 17658590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of asthma control on the severity of virus-induced asthma exacerbations.
    Jackson DJ; Trujillo-Torralbo MB; del-Rosario J; Bartlett NW; Edwards MR; Mallia P; Walton RP; Johnston SL
    J Allergy Clin Immunol; 2015 Aug; 136(2):497-500.e3. PubMed ID: 25772596
    [No Abstract]   [Full Text] [Related]  

  • 6. Toll-like receptor 3 blockade in rhinovirus-induced experimental asthma exacerbations: A randomized controlled study.
    Silkoff PE; Flavin S; Gordon R; Loza MJ; Sterk PJ; Lutter R; Diamant Z; Turner RB; Lipworth BJ; Proud D; Singh D; Eich A; Backer V; Gern JE; Herzmann C; Halperin SA; Mensinga TT; Del Vecchio AM; Branigan P; San Mateo L; Baribaud F; Barnathan ES; Johnston SL
    J Allergy Clin Immunol; 2018 Apr; 141(4):1220-1230. PubMed ID: 28734844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab.
    DuBuske L; Newbold P; Wu Y; Trudo F
    Allergy Asthma Proc; 2018 Sep; 39(5):345-349. PubMed ID: 30077185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of randomized controlled trials for the efficacy and safety of anti-interleukin-13 therapy with lebrikizumab in patients with uncontrolled asthma.
    Liu Y; Zhang S; Chen R; Wei J; Guan G; Zhou M; Dong N; Cao Y
    Allergy Asthma Proc; 2018 Sep; 39(5):332-337. PubMed ID: 30153886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on immunogenicity in severe asthma: Experience with mepolizumab.
    Ortega HG; Meyer E; Brusselle G; Asano K; Prazma CM; Albers FC; Mallett SA; Yancey SW; Gleich GJ
    J Allergy Clin Immunol Pract; 2019; 7(7):2469-2475.e1. PubMed ID: 30954640
    [No Abstract]   [Full Text] [Related]  

  • 10. Epidemiology of asthma exacerbations.
    Sears MR
    J Allergy Clin Immunol; 2008 Oct; 122(4):662-668. PubMed ID: 19014756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lebrikizumab for the treatment of asthma.
    Antoniu SA
    Expert Opin Investig Drugs; 2016 Oct; 25(10):1239-49. PubMed ID: 27554950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma.
    Khorasanizadeh M; Eskian M; Assa'ad AH; Camargo CA; Rezaei N
    Int Rev Immunol; 2016 Jul; 35(4):294-311. PubMed ID: 27119985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eosinophils and interleukin-5: the debate continues.
    Kay AB; Menzies-Gow A
    Am J Respir Crit Care Med; 2003 Jun; 167(12):1586-7. PubMed ID: 12796050
    [No Abstract]   [Full Text] [Related]  

  • 14. [Role of monoclonal anti-IgE antibodies (rhu-MAb) in the treatment of allergic bronchial asthma].
    Targowski T; From S
    Pol Merkur Lekarski; 2003 Jan; 14(79):65-8. PubMed ID: 12712834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mouse models of severe asthma for evaluation of therapeutic cytokine targeting.
    Gubernatorova EO; Namakanova OA; Tumanov AV; Drutskaya MS; Nedospasov SA
    Immunol Lett; 2019 Mar; 207():73-83. PubMed ID: 30659868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of antieosinophil therapy with decreased body mass index in patients with severe asthma: A preliminary retrospective analysis.
    Kuruvilla M; Patrawala M; Levy JM; Shih J; Lee FE
    Ann Allergy Asthma Immunol; 2019 Jun; 122(6):649-650. PubMed ID: 30953786
    [No Abstract]   [Full Text] [Related]  

  • 17. Do early-life viral infections cause asthma?
    Sly PD; Kusel M; Holt PG
    J Allergy Clin Immunol; 2010 Jun; 125(6):1202-5. PubMed ID: 20304476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.
    Djukanović R; Wilson SJ; Kraft M; Jarjour NN; Steel M; Chung KF; Bao W; Fowler-Taylor A; Matthews J; Busse WW; Holgate ST; Fahy JV
    Am J Respir Crit Care Med; 2004 Sep; 170(6):583-93. PubMed ID: 15172898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic and New Therapies in Asthma.
    Tabatabaian F; Ledford DK; Casale TB
    Immunol Allergy Clin North Am; 2017 May; 37(2):329-343. PubMed ID: 28366480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers in the clinical development of asthma therapies.
    Staton TL; Choy DF; Arron JR
    Biomark Med; 2016; 10(2):165-76. PubMed ID: 26764286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.